Ricardo Restrepo-Jaramillo, M.D.

Associate Professor of Medicine, Morsani College of Medicine

University of South Florida, Tampa, Florida

Address

5 Tampa General Circle, Suite 512. Tampa Florida, 33606

Office: (813) 844-7137 Cellular: (215) 964-7399 Email: <u>Ricardo@usf.edu</u>

Education

Universidad Pontificia Bolivariana. Medellin, Colombia.	Jan 1994 -
Medical Diploma: Physician and Surgeon.	Jun 2000

Postgraduate Training

Penn Presbyterian Medical Center, University of Pennsylvania Clinical/ Research Fellow Pulmonary Vascular Disease Program. University of Pennsylvania Health System. Philadelphia, PA	Jul 2013 - Jun 2014
Thomas Jefferson University. Master in Basic Science in Pharmacology. Jefferson Graduate School of Biomedical Science. Philadelphia, PA.	Sep 2011 - Jul 2014
Thomas Jefferson University Hospital. Pulmonary and Critical Care Fellowship. Thomas Jefferson University. Philadelphia, PA.	Jul 2010 - Jun 2013
Abington Memorial Hospital. Internal Medicine Residency. Thomas Jefferson University Health System. Abington PA.	Jun 2007 - Jun 2010

Awards, Honors, Honorary Society Memberships

Resident of the Year. Abington Memorial Hospital	2013
Nesident of the real. Admiston Michighlat Hosbital	2013

Appointments

Associate- Division Director and Director of Clinical Operations. Pulmonary and Critical	May 2022-
Care Division. University of South Florida	Apr 2023

	Associate Professor of Medicine. Morsani College of Medicine University of South Florida	Aug 2022- Present
	Assistant Professor of Medicine . Morsani College of Medicine University of South Florida	Oct 2015 – Jul 2022
	Medical Director Pulmonary Vascular Diseases Center and Pulmonary Hypertension Program. Advanced Lung Disease Center. University of South Florida/Tampa General Hospital. Tampa, Florida.	July 2017 - Present
	Vice-Chief of the Hospital's Department of Internal Medicine, Section of Pulmonary Critical Care. Tampa General Hospital.	Oct 2020 - Present
Teac	hing, Lecture	
	Pulmonary Arterial Hypertension Basics. Pulmonary Critical Care Summer Boot Camp. Teaching lecture Series. Pulmonary and Critical Care Fellowship. Division of Pulmonary and Critical care.	2016 – Present
	Right Ventricular Failure Management in the Intensive Care Unit. Pulmonary Critical Care Summer Boot Camp. Teaching lecture Series. Pulmonary and Critical Care Fellowship. Division of Pulmonary and Critical care.	2016 – Present
	Pulmonary Arterial Hypertension Basics. Sleep Disorders Fellowship. Division of Pulmonary and Critical care.	2018 – Present
	Pleural Effusion Management and Basics. Internal Medicine Residency Lecture Series. Internal Medicine Department.	2015-2020
	Management of Sepsis. Internal Medicine Residency Lecture Series. Internal Medicine Department.	2015-2019
	Management of Critical Care in pregnancy. Maternal Fetal Medicine Department Lecture Series.	2018-2019
Teaching, Supervisory		
	Director of Research Mentor. Tampa General Hospital Section. Pulmonary and Critical Care Fellowship. University. Morsani College of Medicine, University Of South Florida.	2016-2020
	Attending preceptor for Medical Students in the Medical Intensive Care Unit rotation. Morsani College of Medicine, University Of South Florida.	2015 – Present

	Attending preceptor for Foreign Medical Graduates during observer ships in the Medical Intensive Care Unit rotation. Department Of Internal Medicine, University Of South Florida	2015 – Present
	Attending preceptor in clinical management of acute and critically ill adults for master's level nurse practitioner students. College of Nursing University of South Florida.	2018- present
	Attending Mentor for Doctorate Nurse Practitioner Student's research project at Tampa General Hospital. College of Nursing, University of South Florida.	2021 - present
Lecti	ures by Invitation	Date
	Emerging considerations in the management of ILD-PH. 11th Annual Respiratory Congress. Coalicion de Asma y Condiciones Respiratorias Cronicas de Puerto Rico. San Juan. Puerto Rico.	Sep 11, 2023
	PAH description of the Problem. Simposio Latinoamericano de Hipertensión Pulmonar de Niños y Adultos. Panama City. Panama	Oct 21, 2022
	What is New In PAH For 2022. USF Health Department of Internal Medicine Roy H Behnke MD Grand Rounds Lecture Series. University of South Florida. Tampa. Florida	Sep 22, 2022
	ILD-PH a New Entity? Prognosis & Management. 10th Annual Respiratory Congress. Coalicion de Asma y Condiciones Respiratorias Cronicas de Puerto Rico. San Juan. Puerto Rico.	Aug 27, 2022
	Entendiendo la Hypertension Pulmonar Desde su diagnostic Hasta su Cuidado. PHA 2022. International Conference and Scientific Session. Atlanta. Georgia.	June 12, 2022
	Equilibrar la ingesta de sodio y liquidos, asuntos practicos. PHA 2022. International Conference and Scientific Session. Atlanta. Georgia.	June 12, 2022
	What is New in PAH For 2022. Inaugural Naples Cardiovascular Summit. Advances in Cardiology for Primary Care. NCH Heart Institute. Naples. Florida	February 26, 2022
	Hipertension Pulmonar Innovacion y Nuevas Terapias. First Symposium of the Latin-American Coalition for Pulmonary hypertension. Virtual Meeting.	December 2, 2021
	Let's talk about Pulmonary Arterial Hypertension. 9th Annual Respiratory Congress Back to the Basics: Simple to Complex Problems in Pulmonary Diseases. Coalicion de Asma y Condiciones Respiratorias Cronicas de Puerto Rico. San Juan. Puerto Rico.	August 28, 2021
	PAH from Pediatric to Adulthood. Pulmonary Hypertension-Bi-monthly Meeting. Johns Hopkins All Children's Hospital. Tampa. Florida	January 26, 2021
	To add or not to add. Pro-Con debate. XI Latin-American symposium in PAH. Cartagena, Colombia	July 12, 2019

ICU management of PAH and RV Failure. National Lung Association Winter Course. Orlando, Florida	February 17, 2019
"Que Debemos Saber Sobre Hipertension Pulmonar" What do we Need to Know about Pulmonary Hypertension. Colombian meeting for patients with Pulmonary Hypertension. University Fundación Valle De Lili. Cali Colombia.	October 12, 2018
Let's get to know Pulmonary Hypertension. Tampa General Hospital, Transplant by the Bay Meeting. Tampa, Florida.	March 02, 2018
Suspecting Pulmonary Hypertension in the Dyspneic Patient: Who, When, and How. PHA Medical education, Pulmonary Hypertension Association Medical Education Fund. St. Petersburg, Florida.	Nov 14, 2017.
Advanced Therapeutics for Pulmonary Hypertension. David A. Solomon, MD Symposium, Innovations in Pulmonary, Critical Care & Sleep Medicine. Tampa, Florida.	Feb 11, 2017.
PH 101: My PH is not the same as your PH: Understanding how types of PH differ. PHA on the Road: PH Patients and Families Education Forum. Tampa, Florida	Nov 19, 2016.
Pulmonary Hypertension Review . Respiratory Care Conference, Tampa General Hospital. Tampa, Florida.	May 10, 2016.
What a General Physician Should Know About Pulmonary Hypertension. Selected Topics In Cardiology Meeting. University CES. Medellin Colombia.	Aug 14, 2013.
Sleep Apnea and Cardiovascular Complications. Selected Topics In Cardiology Meeting. University CES. Medellin Colombia.	Aug 14, 2013.
Surrogate Endpoints in Pulmonary Hypertension . Pulmonary and Critical Care Grand Round. Pulmonary and Critical Care Division. Thomas Jefferson University Hospital. Philadelphia, PA	May 29, 2013.
"Genetics" Understanding the Bases of PAH. Pulmonary and Critical Care Grand Round. Pulmonary and Critical Care Division. Thomas Jefferson University Hospital. Philadelphia, PA	June 13, 2012.

Research Grants Awarded

Current grants history

Title: RiOciguAt UseRs Registry – The ROAR registryDecemberPotential funds earned: 31,083.7824, 2021

Number of patients enrolled and completed: 0

Funding Source: Bayer Pharmaceutical

Jan 15,

2021

Project Number: 612383110 **Role:** Principal Investigator

Title: Uptravi® (SelexiPag): tHe usErs dRug rEgistry (Sphere AC-065A402)

Nov 2020-**Funds earned:** 11,000

Present

Number of patients enrolled and completed: 1
Funding Source: Pharmaceutical industry funded

Project Number: 6123821800 **Role:** Principal Investigator

Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Present

Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (Acceleron)

Funds earned: 11,000.00

Number of patients enrolled and completed: 0 Funding Source: Pharmaceutical industry funded

Project Number: 6123830400 **Role:** Principal Investigator

Title: A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to
Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary
Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD) RIN-PH-304

Funds earned: 24,717.00

Number of patients enrolled and completed: 0 Funding Source: Pharmaceutical industry funded

Project Number: 6123822700 **Role:** Principal Investigator

Title: An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Nov 2019 - Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Present

Currently Using Tyvaso TIP-PH-101

Funds earned: 134,623.08

Number of patients enrolled and completed: 5 Funding Source: Pharmaceutical industry funded

Project Number: 6123821500 **Role:** Principal Investigator

Title: TDE-PH-401 ADAPT - A Patient Registry of the Real-world Use of Orenitram[®] Sep 2017 - **Funds Earned:** 5,470.40 Present

Number of patients enrolled and completed: 6 Funding Source Pharmaceutical industry funded

Project Number: 6123815100 **Role:** Principal Investigator

Title: A Phase 3, 2-Part, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects With Pulmonary Arterial Hypertension Previously

Stabilized on Inhaled Treprostinil Products.

Funds Earned: 0

Number of patients enrolled and completed: 0 Funding Source Pharmaceutical industry funded

Role: Principal Investigator

Current grants awarded not initiated

Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Oct 21 Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise 2019 Testing in Subjects with World Health Organization Group 1 Pulmonary Hypertension Who Recently Initiated Therapy (ADVANCE Capacity)

Funds Earned: 0

Number of patients enrolled and completed: 0 Funding Source Pharmaceutical industry funded

Role: Principal Investigator

Title: A Study Evaluating the Long-term Efficacy and Safety of Ralinepag in Subjects with PAH via an Open-label Extension (ADVANCE-Extension). 2021

Funds Earned: 0

Number of patients enrolled and completed: 0 Funding Source Pharmaceutical industry funded

Role: Principal Investigator

Title: A Phase 2, Double-blind, Randomized, Placebo controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved

Ejection Fraction (HFpEF) CADENCE. **Potential funds earned:** 281,772.00

Number of patients enrolled and completed: 0 Funding Source: Acceleron Pharmaceutical

Project Number: 61238356 **Role**: Principal Investigator

Title: An International, non drug interventional, real world cohort of PAH patients
newly initiating PAH therapy with guideline directed assessment of disease

2021

Funds Earned: 0

Number of patients enrolled and completed: 0 Funding Source Pharmaceutical industry funded

Role: Principal Investigator

Past grants history

Title: OPsumit USers Registry (OPUS) (AC-055-503) Oct 2016-**Funds Earned:** 7,500.00 Oct 2020 Number of patients enrolled and completed: 16 Funding Source Pharmaceutical industry funded

Project Number: 6123819100 **Role:** Principal Investigator

Title: AC-055-510 Multicenter, Retrospective Chart Review of First-time Opsumit[®] Sep 2017-(Macitentan) Users in the United States Sep 2018

Funds Earned: 138,480.00

Number of patients enrolled and completed: 76 Funding Source Pharmaceutical industry funded

Project Number: 612381750 **Role:** Principal Investigator

Title: Multicenter, randomized, double-blind, placebo-controlled study designed to Dec 2017-investigate the effect of oral treprostinil compared with placebo on exercise capacity in Dec 2019

subjects with WHO Group 2 PH associated with HFpEF. (TDE-HF-301)

Funds Earned: 25,844.15

Number of patients enrolled and completed: 7 Funding Source Pharmaceutical industry funded

Project Number: 6123815200 **Role:** Principal Investigator

Title: An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary
Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction
Oct 2019

(HFpEF) - A Long-term Follow-up to Study (TDE-HF-302)

Funds Earned: 13,679.15

Number of patients enrolled and completed: 4 Funding Source Pharmaceutical industry funded

Project Number: 6123814500 **Role:** Principal Investigator

Title: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate May 2019-the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Jul 2020

Due to Parenchymal Lung Disease (RIN-PH-201)

Funds Earned: 74,014.15

Number of patients enrolled and completed: 13 Funding Source Pharmaceutical industry funded

Project Number: 6123812900 **Role:** Principal Investigator

Title: A multicenter, randomized, double-blind, placebo controlled, 16 week, parallel
Open Label extension, group study designed to investigate the safety and efficacy of
Feb 2021

inhaled treprostinil in subjects with PH-ILD. (RIN-PH-202)

Funds Earned: 31,819.13

Number of patients enrolled and completed: 10 Funding Source Pharmaceutical industry funded

Project Number: 6123812800 **Role:** Principal Investigator

Published Bibliography

Peer-reviewed

Convergent and divergent immune aberrations in COVID-19, post-COVID-19-Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis. Tourki B, Jia M, Karampitsakos T, Vera IM, Arsenault A, Fatima Z, Perrot CY, Allen D, Farsaei F, Rutenberg D, Bandyopadhyay D, Restrepo-Jaramillo R, Qureshi MR, Patel K, Tzouvelekis A, Kapetanaki M, Juan-Guardela B, Kim K, Benos PV, Herazo-Maya JD. Am J Physiol Cell Physiol. Nov 2024. doi: 10.1152/ajpcell.00528.2024. PMID: 39510135

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies. Nick H. Kim. Kelly M. Chin. Vallerie V. McLaughlin. Hilary DuBrock. <u>Ricardo Restrepo-Jaramillo.</u> Zeenat Safdar. Gwen MacDonal. Nicolas Martin. Daniel Rosenberg. Maria Solonets . Richard Channick. Pulm Ther. Jan 2024. **PMID**: 3818450 **DOI**: 10.1007/s41030-023-00251-x

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; <u>STELLAR Trial Investigators</u>. N Engl J Med 2023; 388:1478-1490. **DOI: 10.1056/NEJMoa2213558.**

Long-term Inhaled Treprostinil for Pulmonary Hypertension Due to Interstitial Lung Disease. Aaron Waxman, <u>Ricardo Restrepo-Jaramillo</u>, Thenappan Thenappan, Peter Engel⁴, Abubakr Bajwa, Ashwin Ravichandran, Jeremy Feldman, Amy Hajari Case, Victor Tapson, Peter Smith¹⁰, Chunqin Deng, Eric Shen¹⁰, Steven D. Nathan. European Respiratory Journal. Jan 2023, 2202414; **DOI: 10.1183/13993003.02414-2022**

BREEZE: Open-label Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder as Tyvaso DPI™ in Patients With Pulmonary Arterial Hypertension. Spikes, L.A., Bajwa, A.A., Burger, C.D., Desai, S.V., Eggert, M.S., El-Kersh, K.A., Fisher, M.R., Johri, S., Joly, J.M., Mehta, J., Palevsky, H.I., Ramani, G.V., Restrepo-Jaramillo, R., Sahay, S., Shah, T., Deng, C., Miceli, M., Smith, P. and Shapiro, S.M. *Pulmonary Circulation*. 2022; 12:e12063. **DOI.org/10.1002/pul2.12063**

Delphi Consensus Recommendation for Optimization of Pulmonary Hypertension Therapy Focusing On Switching from a Phosphodiesterase 5 Inhibitor to Riociguat. Rahaghi Franck, Balasubramanian Vijay, Bourge Robert C, Burger Charles, Chakinala Murali, Eggert Michael S, Feldman Jeremy, King Christopher, Palevsky Harold I, Restrepo-Jaramillo Ricardo, Safdar Zeenat, Sager Jeffrey S, Sood Namita, Klinger James, Mathai Stephen, McConnell John, Sulica Roxana, White R James, Hill Nicholas Pulmonary Circulation. 2022; 12:e12055. DOI.org/10.1002/pul2.12055

Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin America. Mauricio Orozco-Levi, Jorge Cáneva, Caio Fernandes, <u>Ricardo Restrepo-Jaramillo</u>, Nayeli Zayas, Rafael Conde, Mirta Diez, Carlos Jardim, Manuel Pacheco, Luciano Melatini, Héctor Glen Valdéz, Tomás Pulido. Pulmonary Circulation. 2022;12:e12012. **DOI.org/10.1002/pul2.12012.**

Perioperative approach to precapillary pulmonary hypertension in non-cardiac non-obstetric surgery. Debabrata Bandyopadhyay, Christopher Lai, Juan N. Pulido, <u>Ricardo Restrepo-Jaramillo</u>, Adriano R. Tonelli, Marc Humbert. Eur Respir Rev 2021; 30: 210166. **DOI: 10.1183/16000617.0166-2021**

Survival and Drug Persistence in Patients Receiving Inhaled Treprostinil at Doses Greater than 54 Mcg (9 Breaths) 4 Times Daily. Shapiro, Shelley M, Mandras, Stacy, Restrepo-Jaramillo, Ricardo, Shen, Eric, Broderick, Meredith, Rao, Youlan, Lee, Dasom, Nelsen, Andrew. Pulmonary Circulation. October 1, 2021. **DOI:10.1177/20458940211052228**

Express. A multicenter, retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil. Diane L Zwicke, <u>Restrepo Jaramillo R</u>, Alnuaimat H, Gordon K, Broderick M, Edwards L, Allmon AG, Leary PJ. Pulmonary Circulation. February 15, 2021. **DOI.org/10.1177/2045894021998203**

The Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Interstitial Lung Disease. Aaron Waxman, MD, PhD, <u>Ricardo Restrepo-Jaramillo</u>, MD, Thenappan Thenappan, MD, Ashwin Ravichandran, MD, Peter Engel, MD, Abubakr Bajwa, MD, Roblee Allen, MD, Jeremy Feldman, MD, Rahul Argula, MD, Peter Smith, PharmD, Kristan Rollins, PharmD, CQ Deng, MD, PhD, Leigh Peterson, PhD, Heidi Bell, MD, Victor Tapson, MD, and Steven D. Nathan, MD. New England Journal of Medicine. January 13, 2021. **DOI: 10.1056/NEJMoa2008470**

The Neutrophil Chemoattractant Peptide Proline-Glycine-Proline Is Associated With Acute Respiratory Distress Syndrome (ARDS). Nirmal Sharma, Charitharth Lal, Jin-dong Li, Xiang-yang Lou, Liliana Viera, Tarek Abdallah, Robert King, Jaskaran Sethi, Prashanth Kanagarajah, Ricardo Restrepo-jaramillo, Amanda Sales-conniff, Shi Wei, Patricia Jackson, J. Edwin Blalock, Amit Gaggar, Xin Xu. Am J Physiol Lung Cell Mol Physiol. 2018 Aug 9. **DOI: 10.1152/ajplung.00308.2017**

Successful use of subcutaneous ivermectin for the treatment of *Strongyloides stercoralis* hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population. Kristen Zeitler, Ripal Jariwala, <u>Ricardo Restrepo-Jaramillo</u>, Shyam Kapadia, Beata Casanas, Sally Alrabaa, Chakrapol Sriaroon. BMJ Case Reports June 4, 2018; **DOI:10.1136/bcr-2017-223138**

Comparing Cardiac Output and Cardiac Index by the Fick and Thermo-dilution Mehods Following an Inhaled Nitric Oxide Challenge in Patients with Pulmonary Arterial Hypertension. Restrepo R, Alvarez M, Schwartz S, Cao K, SriAroon C, Calero K, Clum S, Rumbak M. Pulm Crit Care Med, Volume 2(3): 1-4, 2017. **DOI:0.15761/PCCM.1000140**

One Year Mortality Rates of Tracheostomy Cases: Life after the Knife. Restrepo R, Kahn D, Patel P, Awsare B, Baram M (2015) J Emerg Med Trauma Surg Care 2: 006. **DOI:** 10.24966/ETS-8798/100006

Hepatopulmonary Syndrome and Porto-Pulmonary Hypertension Review. <u>Ricardo Restrepo</u>, Esme F. Singer, Michael Baram. Hospital Practice. April 2013; 41(2):62-71. **DOI:** dx.doi.org/10.3810/hp.2013.04.1049

Do Viral or Host Factors Determine the Severity of Hepatitis A Related Acute Liver Failure? Veeral Ajmera, Yuri Khudyakov, Guoliang Xia, Lilia M. Ganova-Raeva, Christopher K. Opio, Ryan Taylor, <u>Ricardo Restrepo</u>, Santiago Munoz, Robert J. Fontana and William M. Lee. J Viral Hepat. July 2011;18 (7): 167-74. **DOI: 10.1111/j.1365-2893.2010.01410.x**

Abstracts:

A Phase 3, 2-Part, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects with PAH and PH-ILD. N. Habib, R. Restrepo, M. Trivieri, S. Shapiro, C. Burger, S. Patel, A. Galloway, P. Kan, R. Saggar. **Abstract.** ATS meeting May 18-20, 2024

"Inside The Web": Hemodynamic Measurements In Unexpandable Lung. Deepika P. Kulkarni, Ricardo Restrepo Jaramillo, W. Dwight Miller. **Abstract.** ATS meeting May 15-18, 2023

Long-term Effects of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Interstitial Lung Disease: The INCREASE Study Open-label Extension. Aaron Waxman, MD, PhD, <u>Ricardo Restrepo-Jaramillo</u>, Thenappan Thenappan, Ashwin Ravichandran, Peter Engel, Abubakr Bajwa, Jeremy Feldman, Rahul Argula, Peter Smith, Deng, Victor Tapson, Steven D. Nathan. **Abstract.** ATS meeting May 20-23, 2022.

Improved Patient Reported Satisfaction and Outcomes in the Pulmonary Arterial Hypertension (PAH) BREEZE Clinical Tria. El-Kersh K1, Restrepo-Jaramillo R, Spikes L, Smith P, Deng C, Wu B, Classi P. **Abstract.** Economics and Outcomes Research Meeting. May 15-18, 2022.

Peripheral blood gene expression changes predict mortality and treatment response in acute COVID-19 and associate with lung fibrosis. Bochra Tourki, Iset Vera, Carole Perrot, Forouzandeh Farsaei, Alyssa Arsenault, Brenda Juan-Guardela, <u>Ricardo Restrepo</u>, Debabrata Bandyopadhyay, Erol Belli, Gundars Katlaps, Kapilkumar Patel, Stephen Liggett, Kami Kim, Jose Herazo-May. **Abstract.** ATS meeting May 15-18, 2022.

Reverse Bernheim Phenomenon - Always a Conundrum. A. Wulff, M. Islam, R. Restrepo Jaramillo, K. Patel , J. D. Herazo-Maya , D. Bandyopadhyay. **Abstract.** ATS meeting. May 15-18, 2022

Comparison of Pharmacokinetics of 3 Doses of Treprostinil Inhalation Powder (Tyvaso DPI) and 3 Doses of Tyvaso in Healthy Normal Volunteers. Karim El-Kersh, <u>Ricardo Restrepo</u>, Joanna M. Joly, Natalie Pearce, CQ Deng, Melissa Miceli. **Abstract.** ATS meeting May 15-18, 2022.

Central Cannulation of VA-ECMO for Severe Pulmonary Hypertension and Cardiogenic Shock. Shruti Shankar, <u>Ricardo Restrepo</u>, Debabrata Bandyopadhyay, Nirmal Sharma, Kapilkumar Patel. **Abstract.** 51st Critical Care Congress. SCCM. Feb 8, 2022.

BREEZE: Clinical Outcomes and Pharmacokinetics of Treprostinil Inhalation Powder (Tyvaso DPI). Shelley M Shapiro, MD; Leslie A Spikes, MD; Ricardo Restrepo, MD; Joanna M. Joly, MD; Trushil Shah, MD; Jason Scoggin; Lisa Edwards, PhD; Peter M Smith, PharmD; Melissa Miceli, PharmD; Andrew Nelsen, PharmD. Abstract. Chest Meeting 2021.

Clinical Outcomes of Early Ventricular Arrhythmias and Severe Right Ventricular Failure after Left Ventricular Assist Device Implantation. Kieun Seok, Dae Hyun Lee, Richard A Vautier, Fahad Hawk, Deepika Kulkarni, Yuan Yuan Lu, Benjamin Mackie, Ricardo Restrepo-Jaramillo, Zachary Stachura, Guilherme Oliveira, Xavier Prida, Jason Feliberti, Dennis Cassidy, Bengt Herweg. **Abstract**. Circulation. 2020;142:A16371

Hemodynamic Predictors of Right Heart Failure Requiring Right Ventricular Assist Devices After Continuous-flow Left Ventricular Assist Devices Placement. Dae Hyun Lee, Zachary Stachura, Deepika Kulkarni, Jason P Feliberti, <u>Ricardo Restrepo-Jaramillo</u>. **Abstract**. Circulation. 2019;140:A11982

Macitentan in portopulmonary hypertension (PoPH): Real-world data from OPUS and OrPHeUS.Nick Kim, Kelly Chin, Valerie Mclaughlin, Ricardo Restrepo-Jaramillo, Zeenat Safdar, Monika Brand, Megan Flynn, Sandrine Leroy, Adele Morganti, Richard Channick. **Abstract.** European Respiratory Journal. 2019 54: PA5457;

Brotherly Love: A Case of Pulmonary Plasma Cell Granuloma in Twin Brothers. J. Sadik, R. Restrepo-Jaramillo. Abstract. American Journal of Respiratory and Critical Care Medicine 2018;197: A4068

Granulomatosis Polyangiitis in a Patient with Common Variable Immunodeficiency. B. Wolk, MD; S Kapadia, MD; S Clum, MD; R. Restrepo-Jaramillo. **Abstract.** Chest Annual Meeting 2017, Toronto, Canada. Oct 28-Nov 1

Hashimoto's encephalopathy: a rare cause of Altered Mental Status. Kevin L Huang, KL; Restrepo-Jaramillo R. Abstract. Journal of Hospital Medicine. 2017; 12 (suppl 2).

Unusual Case of Collagen Vascular Disease Induced DAH Requiring ECMO. Zachary Gales, Ryan Hoecker, Robert Hooker, Christina Heindel, <u>Ricardo Restrepo</u>, Karel Calero. **Abstract.** Critical Care Medicine: December 2016 - Volume 44 - Issue 12 - p 546

Strongyloides stercoralis: An Inusual Cause of Diffuse Alveolar Hemorrhage in an Immunocompromised Host. Authors: Kapadia, Shyam; Mazalewski, William; Sriaroon, Chakrapol; Restrepo, Ricardo. Abstract. Critical Care Medicine: December 2016 - Volume 44 - Issue 12 - p 516

Outcomes of Increased Plasma-free Hg and blood Transfusions in Patients Receiving ECMO. Hoecker, Ryan; Sriaroon, Chakrapol; Patel, Harsh; Meriwether, William; Restrepo, Ricardo; Calero, Karel. **Abstract.** Critical Care Medicine: December 2016 - Volume 44 - Issue 12 - p 117

Macrophage Activation Syndrome Associated with Atrial Myxoma. <u>Ricardo Restrepo</u>, Nikhil Madan, John Farber, Michael Baram, Bharat Awsare. **Abstract.** Critical Care Medicine. 40;2012 supplement 12: 1269

Diffuse Alveolar Hemorrhage in a Patient with Hemoglobin SC Disease. <u>Ricardo Restrepo</u>, Michael Baram, Omar Ibrahim, Kumar Vipul. **Abstract.** CHEST. 2012,142. 310A

Blood Transfusion- Who Knows What To Do? A Survey of Medical House-Staff. Ricardo Restrepo, Michael Baram, Paul Marik. **Abstract.** CHEST. 2012,142. 537A

Books, Textbooks, Chapters

Pulmonary Hypertension. Selected Topics In Cardiology. University CES. Medellin Colombia. August, 2013

Service

Tampa General Hospital Cardio Thoracic Intensive Care Unit (CTICU) Project Governance Committee. Tampa General Hospital.	Nov 2020– Oct 2023
Diversity, Inclusion, & Community Engagement committee. USF Internal Medicine Department	Nov 2020– Nov 2022

May 2024-

Present

Membership in Professional Associations

American Thoracic Society

American College of Chest Physicians

Pulmonary Hypertension Association **ALAT (Association of Latin American Doctors of thorax)** Honorific membership and member of the Pulmonary vascular diseases Committee

Board Certifications

American Board of Internal Medicine, Internal Medicine 2022-present American Board of Internal Medicine, Pulmonary 2012-present American Board of Internal Medicine, Critical Care 2013-present